Tuesday, June 23, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 650 of 1,261
  1. US 9566251

    Volatile anesthetic compositions and methods of use

    The Board of Regents of the University of Texas System · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted
  2. US 9566232

    Compositions and methods for enhancing the efficacy of contraceptive microbicides

    Evofem, Inc. · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted
  3. US 9562230

    Transferrin/transferrin receptor-mediated siRNA delivery

    Arrowhead Pharmaceuticals, Inc. · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  4. US 9562237

    Reduction of TGF beta signaling in myeloid cells in the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  5. US 9562223

    Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP)

    HALOZYME, INC. · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  6. US 9562070

    Induction of tumor immunity by variants of folate binding protein

    The Board of Regents of the University of Texas System · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  7. US 9562056

    Imidazopyridines Syk inhibitors

    GILEAD CONNECTICUT, INC. · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  8. US 9562073

    Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  9. US 9562100

    Molecules with extended half-lives, compositions and uses thereof

    The Board of Regents of the University of Texas System · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  10. US 9562088

    Pegylated CD154 peptides and methods of inhibiting CD40 interacations with CD154

    The Regents of the University of Colorado, a Body Corporate · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  11. US 9562015

    Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations

    The Regents of the University of Colorado, a body · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  12. US 9562002

    STAT3 inhibitor

    The Board of Regents of the University of Texas System · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  13. US 9561256

    LLP2A-bisphosphonate conjugates for osteoporosis treatment

    The Regents of the University of California · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  14. US 9562020

    Dihydroxy aromatic heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  15. US 9561229

    Emulsion formulations of aprepitant

    Heron Therapeutics, Inc. · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  16. US 9561206

    Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome

    United States of America as represented by the Secretary of the Air Force · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  17. US 9561245

    Combination treatments for melanoma

    The Board of Regents of the University of Texas System · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  18. US 9562039

    Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities

    Almirall, S.A. · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  19. US 9562217

    Modalities for the treatment of degenerative diseases of the retina

    Astellas Institute for Regenerative Medicine · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  20. US 9555041

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jan 31, 2017 · Expires Jan 26, 2037

    granted
  21. US 9556438

    Gene vector

    FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR · Granted Jan 31, 2017 · Expires Jan 26, 2037

    granted
  22. US 9556200

    Tricyclic compound

    Takeda Pharmaceutical Company Limited · Granted Jan 31, 2017 · Expires Jan 26, 2037

    granted
  23. US 9556277

    Method of treating a TL1A-associated disease or disorder with human antibodies to TL1A

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 31, 2017 · Expires Jan 26, 2037

    granted
  24. US 9556237

    Antiviral rift valley fever virus peptides and methods of use

    The United States of America, as represented by the Secretary of the Army, on behalf of the U.S. Army Medical Research Institute of Infectious Diseases · Granted Jan 31, 2017 · Expires Jan 26, 2037

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.